Compares deucravacitinib and apremilast in adults with plaque psoriasis
Compares two psoriasis medicines, deucravacitinib and apremilast, in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Key facts
- Where
- Waltham, United StatesSee the site
Where in United States
- WalthamWaltham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT05744466
- Record updated
- 23 July 2024
- Original description
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.Read full original descriptionShow less
A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Inclusion: Have been diagnosed with plaque psoriasis by a dermatologist; Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast); Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes.
Exclusion: Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history; Participation (current or planned) in an interventional clinical trial (does not include observational registry or study).